18 results
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
23 Mar 10
GTx and Ipsen expand partnership
12:00am
and development of innovative drugs for patient care. In 2009, R&D spend reached close to €200 million, representing more than 19% of total Group sales
8-K
EX-99.1
ONCT
Oncternal Therapeutics Inc
7 Sep 06
Regulation FD Disclosure
12:00am
&D are dedicated to the discovery and development of innovative drugs for patient care. Ipsen’s shares are traded on Segment A of Eurolist by Euronext
S-4
EX-10.49
ONCT
Oncternal Therapeutics Inc
5 Apr 19
Registration of securities issued in business combination transactions
9:02pm
on the discovery and development of innovative drugs and biologies for the treatment of cancer.
C. MD Anderson and Tokalas wish to conduct a research
S-4
h2e 4w7k2
5 Apr 19
Registration of securities issued in business combination transactions
9:02pm
424B3
6qjnh50dx2 i4hfxrzx
8 May 19
Prospectus supplement
12:00am
S-4/A
949tvq
3 May 19
Registration of securities issued in business combination transactions (amended)
9:51pm
- Prev
- 1
- Next